Twist Bioscience Corp vs Vital Farms Inc — how do they compare? Twist Bioscience Corp trades at $154.2 (market cap $10.08B), while Vital Farms Inc trades at $9.45 (market cap $405.27M). The key difference: Twist Bioscience Corp is far larger — about 24.9× Vital Farms Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vital Farms Inc for 14 Days on average.
| TWST | VITL | |
|---|---|---|
Market Cap | $10.08B | $405.27M |
Volume | 4,229,037 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $205.00 | $43.68 |
52-Week Low | $25.45 | $8.28 |
Typical Hold Time | 27 Days | 14 Days |
Enterprise Value | $10.01B | $492.28M |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, reflecting ongoing pressure from weak earnings and industry headwinds. The stock shows a bearish technical trend with key support at $9.00, while fundamentals reveal a sharp decline in profitability with a net margin of just 0.02% in 2026. Recent news highlights strategic review discussions and institutional acquisitions, yet negative cash flow and pricing challenges in the egg market weigh on investor confidence.
The outlook remains cautious with significant execution risks amid industry oversupply, though analyst consensus suggests upside potential to a $13.11 price target. Investment opportunity hinges on a successful strategic review and margin recovery, but risks include sustained cash burn and competitive pressures that could limit near-term gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →